09.04.26 -- Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil

How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies?  Register for 9-15-26 Crossing The Valley Of Death: New Funding Options For Preclinical And Early-Stage Drug Development for free and learn from an experienced panel of experts about key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises.

Discover how funding, executive guidance, market intelligence, and research partnerships are helping life sciences startups overcome commercialization barriers and scale promising innovations.

Artificial intelligence is expanding from the preclinical phase of clinical trials into Phases I–III, where is it being used in protocol design, site selection, feasibility, and patient recruitment.

Embedded medical information expertise enabled compliant, real‑time scientific engagement with healthcare professionals at a high‑profile congress during a critical product launch.

Explore how eSource is advancing clinical trials through smarter data capture, improved quality, faster execution, and more connected digital study operations.

Bioprocessing produces more data than ever, but many organizations still struggle to turn it into action. Better integration can support faster decisions and more predictable performance.

Up to 40% of clinical trial referrals drop off before screening due to financial, logistical, and administrative hurdles. Streamlining coordination and easing patient burden can boost enrollment.

See how one family managed to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

Japan's pharma market requires J-DMF registration, Foreign Manufacturer Accreditation, and GMP compliance. Expert CDMO support streamlines PMDA submissions and speeds market entry.